Spire Healthcare Group (LON:SPI) Trading Down 21.4% After Analyst Downgrade

Spire Healthcare Group plc (LON:SPI) fell 21.4% on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 176.40 ($2.28). 3,426,506 shares were traded during trading, an increase of 447% from the average session volume of 626,257 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Down 6.0 %

The business has a 50 day moving average of GBX 227.28 and a two-hundred day moving average of GBX 229.74. The company has a debt-to-equity ratio of 62.25, a quick ratio of 0.74 and a current ratio of 0.70. The stock has a market capitalization of £711.58 million, a PE ratio of 25.22, a PEG ratio of 1.06 and a beta of 0.96.

Spire Healthcare Group (LON:SPI) last released its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) EPS for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. Analysts predict that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.